A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.

ABSTRACT:

Background

Apixaban and rivaroxaban are commonly used direct oral anticoagulants for atrial fibrillation (AF) and venous thromboembolism (VTE). Both have been compared to warfarin, but there are insufficient comparative outcome data.

Objectives

The purpose of this study was to assess outcomes of apixaban, rivaroxaban, and warfarin.

Methods

This is a registry-based cohort study with data from 6 centers in Michigan, 2009 to 2023. Patients were adults with AF and/or VTE with at least 3 months of follow-up. Outcomes included rates of bleeding, thrombosis, healthcare utilization, and death.

Results

A total of 13,435 patients met the study inclusion criteria (average age 66.7 years, 58.0% on anticoagulation for AF, average follow-up 28.2 months). After matching, 2 gr

SUBMITTER: Schaefer JK 

PROVIDER: S-EPMC12235406 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature